ライブ
FierceBiotechChutes & Ladders—Helus shuffles out CEO after two months, adds experience to science boardFierceBiotechAfter Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?BioWorldSichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonistsBioWorldShanghai Meiyue Biotech Development presents new molecular glue degradersBioWorldJiangsu Carephar Pharmaceutical describes new AT2 receptor agonistsBioWorldPharma industry faces long haul to get return on investment from AIFierceBiotechAvalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugsThermo FisherThermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo FinanceAgilentDoes Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpaceThermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking Alpha
Endpoints News 2025年12月15日

Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront

Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront

原文
本文は利用できません。元の情報源をご確認ください。